StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Down 2.7 %

Aptose Biosciences stock opened at $0.38 on Wednesday. The business has a 50-day simple moving average of $0.38 and a 200 day simple moving average of $0.65. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $2.97. The stock has a market cap of $6.89 million, a price-to-earnings ratio of -0.13 and a beta of 1.26.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.